WASHINGTON (Reuters) - Use of antibiotic drugs such as Bayer AG’s Cipro can lead to tendinitis and ruptured tendons, U.S. health regulators said on Tuesday, calling for new strong warnings on the products.
The so-called black box warning would also apply to Bayer’s Avelox, Oscient Pharmaceuticals Corp’s Factive, Daiichi Sankyo Co Ltd’s Floxin, and Depomed Inc’s Proquin.
It would also affect Johnson & Johnson’s Levaquin and norfloxacin, which has been marketed as Noroxin by Merck & Co Inc. It was not immediately clear whether Merck still sells the product and representatives for the company had no immediate comment.
After the warning, shares of Oscient fell more than 3 percent on the Nasdaq before recovering to trade down 1.42 percent at $1.39 in late morning trade. Shares of Bayer and Daiichi were both off less than 1 percent on the German and Tokyo exchanges. Depomed shares were up 5.4 percent at $3.31, also on the Nasdaq.
Labels for the antibiotics already include cautions about the tendon problems, but the bolder, boxed warning would be stronger, the FDA said.
The risk is greater in patients 60 and older, those who have had certain organ transplants and those using concomitant
steroid therapy, the agency said. It added doctors should restrict use of the drugs to conditions clearly caused by bacteria.
Shares of Merck were up 1.6 percent at $37.20 while shares of Johnson & Johnson were up 1.4 percent at $66.14, both in late morning trade on the New York Stock Exchange.
Reporting by Susan Heavey, editing by Gerald E. McCormick
Our Standards: The Thomson Reuters Trust Principles.